Humacyte, Inc.
Public company- Headquarters
- DURHAM, North Carolina
- Industry
- Biotechnology
- Ticker
- HUMA
- CIK
- 0001818382
WARN notices since 2024
0
None on record
Workers affected since 2024
0
Across 0 notices
Executive changes, last 12 months
2
2 appointments, 0 departures
Last event
Sep 28, 2026
Executive appointmentClass I director appointed: Scott Coward
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class I directorScott Coward | Sep 28, 2026 | Appointed |
| Class II directorPaul Kuznik | Sep 28, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- BIOCRYST PHARMACEUTICALS INC
Plant closure: Hoover, AL
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- Executive appointment
Class I director appointed: Scott Coward
Scott Coward was named Class I director of Humacyte, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 28, 2026Role: Class I director
- Executive appointment
Class II director appointed: Paul Kuznik
Paul Kuznik was named Class II director of Humacyte, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 28, 2026Role: Class II director
Last verified Nov 8, 2026